Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
An options-market snapshot suggests Salesforce shares are being valued with expectations for a broader swing than the stock’s most recent one-year performance, with volatility costs that appear typical rather than unusually cheap.
THE APEX TIMES
THE APEX TIMES
A melanoma trial win is prompting Wall Street to rethink how it values Moderna’s oncology pipeline, with Jefferies arguing that the company’s broader platform could be worth more than investors had been assigning it.
THE APEX TIMES
In a note cited by market media, Bank of America said Zoom’s post-pandemic reset may be nearing an end, with newer offerings and improving customer retention reshaping the outlook.
THE APEX TIMES
Moderna’s stock jumped roughly 170% to 177% following news described as a major cancer vaccine breakthrough, reigniting investor debate over near-term upside and the durability of expectations around the company’s pipeline.
THE APEX TIMES
A market analysis frames Pfizer’s near-term outlook as a balancing act between revenue slipping from expiring patents and new medicines moving toward commercialization through launches and acquisitions.
THE APEX TIMES
A new expansion to Amazon’s automation push, first reported by Yahoo Finance, highlights how the company is trying to improve speed and lower the cost of fulfilling online orders, even as labor and logistics remain major pressures in retail.
THE APEX TIMES
In a note flagged by Yahoo Finance, BNP Paribas suggested Meta’s next phase of costly infrastructure investment could support another growth engine, even as investors weigh near-term spending and execution risk.
THE APEX TIMES
“Sterling Point,” starring Ella Rubin and Jeffery Dean Morgan, was renewed for a second season after launching to a No. 1 global debut on Prime Video.
THE APEX TIMES
In a new post, Google says its open Gemma AI model family has surpassed a billion downloads, pointing to deployments ranging from satellites to health applications and new research built on Gemma-derived systems.
